Haemorrhagic disorder due to ventricular assist device KU Leuven
The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.